Advertisement

Picture EBD Group BIO-Europe 2018 Copenhagen Denmark Partnerships 600x60px
Document › Details

Boehringer Ingelheim. (7/22/14). "Press Release: Boehringer Ingelheim Establishes a Research Alliance with the University of Toronto, the Toronto-based University Health Network and the Mount Sinai Hospital to Investigate New Therapeutic Concepts in the

Organisations Organisation Boehringer Ingelheim (Group)
  Organisation 2 University of Toronto
Products Product drug target identification
  Product 2 drug discovery
Index term Index term Boehringer–Univ Toronto: drug target discovery, 201407– collab to characterise new drug targets in ubiquitin system
Person Person Pairet, Michel (Boehringer 201009 head Boehringer Ingelheim Venture Fund)
     


Boehringer Ingelheim Establishes a Research Alliance with the University of Toronto, the Toronto-based University Health Network and the Mount Sinai Hospital to investigate new therapeutic concepts in the field of ubiquitin signalling biology


Boehringer Ingelheim announced today that it has established a research alliance with the University of Toronto through the Toronto Recombinant Antibody Centre (TRAC), together with Toronto-based University Health Network and Mount Sinai Hospital to characterize new therapeutic targets in the field of ubiquitin biology. Alterations of the ubiquitin system are linked to many common diseases such as cancer, diabetes, inflammation and several central nervous system disorders. Boehringer Ingelheim scientists will work closely with leading scientists in the Toronto academic community to explore different therapeutic concepts within the ubiquitin system, a highly attractive and potentially rich area of unprecedented drug targets.

Under the terms of the agreement the research capabilities of the three research institutes and Boehringer Ingelheim will be brought together to provide novel starting points for drug discovery in a multi-year research program focusing on the development and characterization of novel ubiquitin binding variants developed at the TRAC. Further details of the agreement are not disclosed.

"We are very pleased to work closely in a joint research program with the distinguished scientists at the University of Toronto, the University Health Network and the Mount Sinai Hospital in this emerging field of breakthrough therapeutics" said Dr Michel Pairet, Senior Corporate Vice President of Research and Non-clinical Development at Boehringer Ingelheim. He added, "We believe that this research program, headed by Sachdev Sidhu at the University of Toronto, will further strengthen our strong commitment in initiating new drug discovery programmes in areas of high unmet medical need."


About University of Toronto

Ranked 20th in the Times Higher Education 2013 World University Rankings, the University of Toronto has a rich research history which includes the discovery of insulin, Marshall McLuhan's "the medium is the message" and 10 Nobel Prizes among our faculty and alumni. Today, our research endeavour is a formidable force spanning three campuses and nine partner hospitals, with annual research income totaling $1.2 billion. U of T researchers publish more articles than peers at any university other than Harvard. As a measure of impact, U of T consistently ranks alongside the top five U.S. universities on articles cited and it currently leads North America in number of start-up companies created.


About University Health Network

University Health Network includes Toronto General and Toronto Western Hospitals, Princess Margaret Cancer Centre, and Toronto Rehabilitation Institute. The scope of research and complexity of cases at University Health Network has made it a national and international source for discovery, education and patient care. It has the largest hospital-based research program in Canada, with major research in cardiology, transplantation, neurosciences, oncology, surgical innovation, infectious diseases, genomic medicine and rehabilitation medicine. University Health Network is a research hospital affiliated with the University of Toronto. www.uhn.ca


About Mount Sinai Hospital

Mount Sinai Hospital is an internationally recognized, 472-bed acute care academic health sciences centre affiliated with University of Toronto. It is known for excellence in the provision of compassionate patient care, innovative education, and leading-edge research at Lunenfeld-Tanenbaum Research Institute (www.lunenfeld.ca).

Mount Sinai's Centres of Excellence include the Lunenfeld-Tanenbaum Research Institute; Women's and Infants' Health; Surgery and Oncology; Acute and Chronic Medicine, and Laboratory Medicine and Infection Control.

Mount Sinai Hospital brings together Bright Minds and Big Hearts to provide The Best Medicine. www.mountsinai.on.ca


About Boehringer Ingelheim

The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, Boehringer Ingelheim operates globally with 142 affiliates and a total of more than 47,400 employees. The focus of the family-owned company, founded in 1885, is researching, developing, manufacturing and marketing new medications of high therapeutic value for human and veterinary medicine. The Canadian headquarters of Boehringer Ingelheim was established in 1972 in Montreal, Quebec and is now located in Burlington, Ontario. Boehringer Ingelheim employs more than 550 people across Canada, offering prescription and CHC medicines to patients in Canada.

Taking social responsibility is an important element of the corporate culture at Boehringer Ingelheim. This includes worldwide involvement in social projects, such as the initiative "Making more Health" and caring for the employees. Respect, equal opportunities and reconciling career and family form the foundation of the mutual cooperation. In everything it does, the company focuses on environmental protection and sustainability.

In 2013, Boehringer Ingelheim achieved net sales of about 14.1 billion euros. R&D expenditure corresponds to 19.5% of its net sales.

For more information please visit www.boehringer-ingelheim.com

Media & PR
Dr Reinhard Malin
Binger Strasse 173
55216 Ingelheim am Rhein

GERMANY
Phone + 49 - 6132 - 77 90815
Fax + 49 - 6132 - 77 6601

Boehringer Ingelheim US (for US media enquiries)
Susan Holz
Director, Public Relations - Oncology & HCV
Boehringer Ingelheim Pharmaceuticals, Inc.
Ridgefield, CT
Tel.: +1 (203) 798-4265
susan.holz@boehringer-ingelheim.com

   
Record changed: 2017-04-02

Advertisement

Picture Berlin Partner HealthCapital RegMed Forum 2018 October iito 600x60px

More documents for Boehringer Ingelheim (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture Berlin Partner HealthCapital RegMed Forum 2018 October 600x60px




» top